High Science 2010: Rising To The Challenge Of Driving Medtech Innovation In Turbulent Times
Medtech R&D productivity is being undermined by a range of deep-seated changes in the health care industry. Companies that underestimate this challenge face the prospect of lackluster growth over the long term. But in sharp contrast, Boston Consulting Group has identified a set of "High Science" device companies that are making a concerted effort to reinvent their approach to R&D and gain a competitive edge.
You may also be interested in...
While all of the attention is focused on US health care reform and how it may hurt medical technology, China is undertaking massive reform of its own, which looks to be a boon, first for equipment and diagnostics, then for devices.
The Boston Consulting Group reveals results of a study on how medical technology firms can cultivate and manage their R&D to boost revenue, profits, and even and stock valuations.
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.